PR96312

NANJING, China, June 2, 2022 /PRNewswire=KYODO JBN/--

Vazyme, China's leading biotechnology company, has recently released its 2021

annual report, revealing that the company has maintained a steady and solid

growth throughout the past year. The report shows that it has achieved $289

million in operating income with an increase of 19.44% year-on-year. The

company's R&D investment reached $36 million, up 83.47%, representing 12.33% of

its total operating income.

"The year 2022 is still full of opportunities and challenges. We will continue

to strengthen care technology based on the protein technology platform. Vazyme

has been dedicated to our mission 'Science and Technology Make a Healthier

Life' to focus on technology innovation and continuously expand the application

fields of care technologies in life science, biomedicine, in vitro diagnostics,

animal health and synthetic biology in human health. We have been holding

ourselves to pursue the highest standards in quality of products and services

for our customers and partners. Our global business network and operations make

sure we could be close to the local markets, and more importantly, to do as

much it can to meet the unmet customers' needs", said Cao Lin, chairman and

founder of Vazyme.

This year also marks the Vazyme's 10th anniversary. Moving forward, the company

plans to ramp up efforts in R&D and innovation, continuously upgrade and

transform its core technologies, and expand business in new sectors. As one of

the few R&D-focused biotech company in China, Vazyme holds a longstanding

commitment in technology innovation. Over 2000 papers have been published by

Vazyme in top academic journals worldwide, including more than 260 in

CNS(stands for Cell, Nature, Science). By 2022, it has some 3000 employees and

27% of that are in the R&D team.

"Looking ahead, we will make further inroads in our key businesses and expand

into new domains. I believe the market demand for COVID-19 and other related

detection materials and products will continue to be strong. During the

pandemic, China has remained one of the largest supplier for COVID-19 detection

products." said Cao. In addition to pandemic-induced detection businesses,

other regular detection products will be further developed, according to Cao.

"When the prevention and control of the pandemic become regular, there will be

new demands for detection products. In the future we will focus on the

development of that," added Cao.

Vazyme can not only provide COVID-19 and other related detection materials and

products, but only offer various products and solutions in life-science

industry for universities, laboratories, and related R&D centers, such as

scientific research reagents, NGS Library Prep Kits and molecular diagnostics

solutions. Currently, Vazyme has over 200 kinds of genetic engineering

recombinases, more than 1,000 kinds of high-performance antigens, monoclonal

antibodies, and other key raw materials, in addition to over 600 finished

products.

As Vazyme's 10th anniversary slogan "Together for a Better Future", Vazyme aims

to get close to its partners for a better future. In the future, Vazyme will

provide better products and solutions, contribute to improve R&D efficiency for

its partners, realize more scientific breakthroughs and dedicating to the

mission "Science and Technology Make a Healthier Life".

SOURCE: Vazyme

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=422623

   Caption: Vazyme